$NYMX Lol HFH and White Diamond Research vs. some of the most renowned urology researchers in the world. I posted a journal article couple days ago authored by Shore, Tutrone, and Roehrborn, worth reading. And past president of the AUA - New York Section Ivan Grunberger predicted a couple years ago that fexapotide would become the first-line BPH treatment when approved. Yet they only need 10%-15% of patients to hit $5B+ in revs. And btw, stock will be added to the R2K small cap index in June; indexers will need several million shares. Shorts are gonna get smoked!